Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t131705eu1
  1. Home
  2. T 1705/13 (Proteolytic antibodies/SUDHIR AND YASUHIRO) 16-05-2017
Facebook Twitter Linkedin Email

T 1705/13 (Proteolytic antibodies/SUDHIR AND YASUHIRO) 16-05-2017

European Case Law Identifier
ECLI:EP:BA:2017:T170513.20170516
Date of decision
16 May 2017
Case number
T 1705/13
Petition for review of
-
Application number
04758448.7
IPC class
C07K 16/10
C07K 16/28
C07K 16/44
C12Q 1/70
C12N 5/06
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 359.8 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Proteolytic and covalent antibodies

Applicant name

Paul, Sudhir

Nishiyama, Yasuhiro

Opponent name
-
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)
European Patent Convention Art 54
European Patent Convention Art 87
European Patent Convention Art 88
European Patent Convention Art 89
European Patent Convention Art 111(1)
Keywords

Main request - novelty (no)

Auxiliary request - novelty (yes)

Appeal decision - remittal to the department of first instance (yes)

Catchword
-
Cited decisions
G 0001/15
Citing decisions
-

I. The appeal of the applicants (hereinafter "appellants") lies against the decision of the examining division refusing European patent application No. 04 758 448.7.

II. The application at issue has the title "Proteolytic and covalent antibodies" and claims priority of US application No. 60/458,063, filed on 26 March 2003 (hereinafter "P1") and US application No. 60/534,689, filed on 8 January 2004 (hereinafter "P2").

III. The following documents are referred to in this decision:

D7 Planque S. et al., Journal of Biological Chemistry (31 March 2003), vol. 278, pages 20436 to 20443.

D8 Nishiyama Y. et al., Journal of Biological Chemistry (15 December 2003), vol. 279, pages 7877 to 7883.

D11 Paul, S. et al., Journal of Biological Chemistry (28 March 2003), vol. 278, pages 20429 to 20435.

D15 Nishiyama Y. et al., Archives of Biochemistry and Biophysics (2002), vol. 402, pages 281 to 288.

IV. The examining division held that the subject-matter of claim 11 of the main request before it failed to comply with the requirements of Article 123(2) EPC (see decision under appeal, point 3.1), that the subject-matter of claim 9 was excluded from patentability pursuant to Article 53(c) EPC (ibid., point 6), that claim 1 lacked clarity due to the use of the term "covalent antibody" and that claim 7 lacked clarity and should be reformulated to read "for use in a method of stimulating" (ibid., point 7). It further held that the subject-matter of the claims of the main request before it was not entitled to the priority of P1 and that documents D7, D8 and D11 were thus state of the art (ibid., point 4). Document D7 was considered to anticipate the subject-matter of claims 1 to 5, 8, and 10, while documents D8 and D11 were considered to anticipate the subject-matter of claims 1 to 5, 8, 10 and 11 of the main request (ibid., point 8). The subject-matter of auxiliary request 1 was considered to extend beyond the application as filed (ibid., point 10), while for auxiliary request 2 the requirements of Article 123(2) EPC were considered to be fulfilled while otherwise the same objections as for the main request were raised (ibid., points 15 to 21). In an obiter dictum the examining division commented on the inventive step of the claimed subject-matter.

V. With their statement of grounds of appeal the appellants filed a main request and auxiliary requests I to III.

VI. The appellants were summoned for oral proceedings and subsequently informed of the board's preliminary opinion in a communication under Article 15(1) RPBA. Document D15 was introduced into the proceedings by the board.

VII. In response, the appellants withdrew the pending claim requests and filed a new main request and auxiliary requests I to IV.

VIII. At the oral proceedings before the board the appellants replaced their pending main request with a new main request, filed a new auxiliary request and withdrew pending auxiliary requests I to IV.

Claim 1 of the new main request reads:

"1. A method of preparing antibodies that bind covalently to a polypeptide or bind covalently and proteolytically cleave said polypeptide, the method comprising isolating the antibodies from an ex vivo sample obtained from an organism using a covalently reactive polypeptide analogue (pCRA) comprising an antigenic determinant of formula (I):FORMULA/TABLE/GRAPHIC

wherein:

LI... Lx... Lm are, together, 4-30 amino acid components of said antigenic determinant of said polypeptide,

Lx is an amino acid determinant which is not a terminal amino acid,

L' is a side-chain functional group of Lx,

Y" is atom, covalent bond or flexible linker,

Y is a covalently reactive electrophilic group that reacts with said antibodies, and wherein the covalently reactive electrophilic group is located in an amino acid side-chain of the antigenic determinant."

Claim 1 of the auxiliary request reads:

1. "A method of preparing antibodies that bind covalently to a polypeptide or bind covalently and proteolytically cleave said polypeptide, the method comprising isolating the antibodies from an ex vivo sample obtained from an organism which was previously immunized using a covalently reactive polypeptide analogue (pCRA) comprising an antigenic determinant of formula (I):

FORMULA/TABLE/GRAPHIC

wherein:

LI... Lx... Lm are, together, 4-30 amino acid components of said antigenic determinant of said polypeptide,

Lx is an amino acid determinant which is not a terminal amino acid,

L' is a side-chain functional group of Lx,

Y" is atom, covalent bond or flexible linker,

Y is a covalently reactive electrophilic group that reacts with said antibodies, and wherein the covalently reactive electrophilic group is located in an amino acid side-chain of the antigenic determinant."

Claims 2 to 4 of the auxiliary request are dependent on claim 1.

Claim 9 of the auxiliary request reads:

"9. The composition according to claim 8 for use as a medicament wherein the medical disorder is an infectious disease, HIV, a cancer, or an autoimmune disease."

At the end of the oral proceedings the chairwoman announced the board's decision.

IX. The arguments of the appellants submitted in writing and during the oral proceedings and relevant for the present decision may be summarised as follows:

Main request

Claim construction - claim 1

In the context of the method of claim 1 the feature "isolating the antibodies from an ex vivo sample obtained from an organism using a covalently reactive polypeptide analogue (pCRA)" covered any possible use of the pCRA to isolate the antibodies, including incubating the ex vivo sample with the pCRA and isolation of the resulting complex from the other antibodies in the sample.

Amendments (Article 123(2) EPC) - claim 1

The subject-matter of claim 1 found basis in the application as filed on page 25, lines 9 to 14 in combination with claim 1 and page 22, line 30 to page 23, line 8.

Priority (Articles 87 to 89 EPC) - claim 1

The claims of P1 in combination with the legend of Figure 7a and the example disclosed directly and unambiguously the subject-matter of claim 1. In P1, pCRA was used to identify the hybridomas that produced the antibodies, see the second paragraph on page 6. Electrophoresis of antibody-CRA complexes was disclosed on page 7, second paragraph of P1. As P1 provided a basis for the wording of claim 1 it did not need to disclose all embodiments falling within the scope of claim 1 of the main request to give rise to a right of priority.

Novelty (Article 54 EPC) - claim 1

Document D7 was not novelty-destroying because the subject-matter of claim 1 was entitled to priority from P1.

Auxiliary request

Amendments (Article 123(2) EPC) - claims 1 to 4 and 9

Basis for the subject-matter of claims 1 to 4 and 9 was provided in the application as filed on page 4, lines 10 to 25, in combination with the disclosure in the examples and the claims.

Priority (Articles 87 to 89 EPC) - claims 1 to 4 and 9

That part of the subject-matter of claims 1 to 4 and 9 that was disclosed in document D11 was entitled to priority from P1.

Novelty (Article 54 EPC) - claims 1 to 4, 9 and 10

The method according to claim 1 differed from the method disclosed in document D7 in that pCRA was used for immunisation. Document D7 did not disclose any medical use of the pCRA.

In document D8 the pCRA was used to inactivate catalytic antibodies, not to isolate them. The antibodies targeted in document D8 were not known to be involved in any kind of pathology, accordingly no medical use was disclosed in document D8.

As the pCRA disclosed in document D15 did not have an electrophilic group it did not fall within the scope of claim 10.

X. The appellants requested that the decision under appeal be set aside and a patent be granted on the basis of the set of claims of the main request or, alternatively, on the set of claims of the auxiliary request.

The appeal complies with Articles 106 to 108 and Rule 99 EPC and is therefore admissible.

Main request

Claim construction - claim 1

1. The method according to claim 1 comprises the step of "isolating the antibodies from an ex vivo sample obtained from an organism using a covalently reactive polypeptide analogue (pCRA)". This step is understood to encompass inter alia the use of the pCRA in the screening of hybridoma supernatants but also the use of the pCRA to isolate antibodies directly from the ex vivo sample by forming pCRA-antibody adducts, see also the application as filed on page 4, lines 23 to 26, page 25, lines 9 to 15, and page 51, line 32 to page 52, lines 9 and claims 1, 11, and 12.

Article 123(2) EPC - claim 1

2. The board is satisfied that the subject-matter of claim 1 finds basis in the application as filed on page 4, lines 10 to 23, in combination with the disclosure on page 25, lines 9 to 14, and on page 22, line 30, to page 23, line 8, and claim 1.

Priority (Articles 87 to 89 EPC) - claim 1

3. P1 discloses a method of preparing antibodies that bind covalently to a polypeptide (see page 6, second paragraph, to page 10, first paragraph, legend of

Fig. 7A on page 22, claims 1, 7). A pCRA comprising an antigenic determinant of formula (I) as defined in present claim 1 is disclosed in P1 on page 22, second paragraph in combination with the formula depicted in claim 1 of P1. According to P1 the antibodies are isolated by generating hybridomas, screening of the supernatants from the hybridoma wells for SDS-resistant binding to CRA and identification of wells secreting the desired Abs. Following cloning of the cells by limiting dilution, monoclonal IgG is purified. Irreversible binding of biotinylated CRAs by purified IgG is determined by denaturing electrophoresis.

4. P1 thus discloses one specific method for preparing antibodies that bind covalently to a polypeptide which comprises isolating antibodies from an ex vivo sample obtained from an organism using a pCRA, i.e. the method used in the example of P1 which involves the use of pCRA in the screening of hybridoma supernatants.

5. The appellants submitted that P1 also disclosed electrophoresis on page 7 and that the subject-matter of claim 1 was thus also entitled to priority for embodiments involving electrophoresis.

6. The board found this argument not persuasive. According to P1, electrophoresis is not used for isolating the antibodies from the ex vivo sample but for determining irreversible binding of CRA to the antibodies (see point 3).

7. The appellants further submitted that it was not necessary for P1 to disclose all embodiments falling within the scope of claim 1 as long as P1 provided a basis for the wording of claim 1.

8. Given the interpretation of claim 1 (see point 1) and the disclosure in P1 (see point 4) the board considers however that the subject-matter of claim 1 relates to a generalisation compared to the invention disclosed in P1. The embodiment disclosed in P1 is encompassed, albeit without being spelt out, in the method of claim 1.

9. The subject-matter of claim 1 can thus be conceptually divided into two parts. The first part corresponding to the invention disclosed directly and unambiguously in P1 (see point 4) and entitled to priority from P1, the second part being the remaining subject-matter of claim 1, which is not entitled to the priority of P1 and which encompasses embodiments that involve the use of pCRAs to isolate antibodies, wherein the antibodies form adducts with the pCRAs, which are then isolated from the ex vivo sample (see point 1), see also decision of the Enlarged Board of Appeal G 1/15 of 29 November 2016, in particular points 5.1.2, 5.1.3 and 6.4.

Novelty (Article 54) - claim 1

10. Document D7 belongs to the state of the art pursuant to Article 54(2) EPC for that part of the subject-matter of claim 1 which is not entitled to the priority of P1 (see point 9).

11. Document D7 discloses the preparation of antibodies that bind covalently to the extracellular domain of human epidermal growth factor receptor (exEGFR) protein by immunising mice with exEGFR and then isolating antibodies from immune sera by using a covalently reactive antigen analog of exEGFR, namely CRA IV, to form adducts with the antibodies. That the antibodies bind covalently to CRA IV is shown by denaturing electrophoresis (see page 20 437, left-hand column, third paragraph; page 20 439, right-hand column, last paragraph to page 20 441, left-hand column, first paragraph; Figures 5 and 6). CRA IV consists of exEGFR which presents diverse antigenic epitopes derivatised at Lys side chains with a phosphonate diester (see Fig. 1C). Therefore, document D7 is considered to disclose a method of preparing antibodies that bind covalently to a polypeptide which method falls within the scope of claim 1. This was not disputed by the appellants.

12. Therefore, the board concludes that the disclosure of document D7 anticipates the subject-matter of claim 1 of the main request, which thus fails the requirements of Article 54(2) EPC.

Auxiliary request

13. The present auxiliary request does not include claims 1, 8 and 11 of the main request before the examining division. The claims that correspond to claims 2 to 5, and 10 of said main request are claims 1 to 4 and 9 of the auxiliary request.

Article 123(2) EPC - claims 1 to 4 and 9

14. The board is satisfied that the subject-matter of claims 1 to 4 and 9 finds a basis in the application as filed on page 4, lines 10 to 25, in combination with the disclosure on page 25, lines 9 to 14, and on page 22, line 30, to page 23, line 8, Example II and claims 1, 11, and 12.

Priority (Articles 87 to 89 EPC)- claims 1 to 4 and 9

15. The examining division held that the subject-matter of the main request before it was not entitled to the priority of P1 and that documents D7, D8 and D11 thus belonged to the state of the art for the claimed subject-matter (see decision under appeal, points 4.3 to 4.3.8). It further held that document D7 anticipated the subject-matter of claims 1 to 5, 8 and 10, while documents D8 and D11 were considered to anticipate the subject-matter of claims 1 to 5, 8, 10 and 11 of the main request before it then (see decision under appeal, points 8 to 8.3).

16. The board considers, in line with decision G 1/15, supra, that the subject-matter of claims 1 to 4 and 9 of the auxiliary request enjoys partial priority for that part of its subject-matter that is directly and unambiguously disclosed in P1.

17. Document D11 (see abstract, page 20 429, left-hand column, first paragraph, to page 20 435, right-hand column, second paragraph) is the scientific publication corresponding to P1 (see page 1 to 21, claims, figures). In the board's judgement, the disclosure of document D11 does not extend beyond the content of P1.

18. It follows that document D11 does not belong to the state of the art pursuant to Article 54(2) EPC for that part of the subject-matter of claims 1 to 4 and 9 that is entitled to the priority of P1.

19. Since neither document D7 nor document D8 are considered to disclose subject-matter falling within the scope of claims 1 to 4 and 9 of the auxiliary request (see below, points 20 to 22), it need not be decided for the purpose of this decision whether or not the subject-matter of claims 1 to 4 and 9 is entitled to P1 with regard to that prior art.

Novelty (Article 54 EPC) - claims 1 to 4, 9 and 10

20. The method disclosed in document D7 differs from the method of claim 1 in that the pCRA is not used for immunisation (see above point 11). Accordingly, document D7 does not anticipate the subject-matter of claim 1 or of its dependent claims 2 to 4. Since document D7 does not disclose any medical use of the pCRA it does not disclose the subject-matter of claim 9 either.

21. Document D8 reports the selective inactivation of proteolytic antibodies to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently reactive analog (CRA) of VIP, termed VIP-CRA (see compound 3 in Fig. 1A). The VIP-CRA is bound irreversibly by a monoclonal antibody (mAb) that catalyses the hydrolysis of VIP (see abstract). This antibody, mAb c23.5, was raised by hyper-immunisation with VIP not with pCRA (see page 7878, right-hand column, last paragraph). Therefore, document D8 does not anticipate the subject-matter of claim 1 or of its dependent claims 2 to 4. Since document D8 does not disclose any medical use of the pCRA it does not disclose the subject-matter of claim 9 either.

22. The board concludes that the subject-matter of claims 1 to 4 and 9 is not anticipated by the disclosure of documents D7 and D8.

23. Document D15 had been introduced by the board into the proceedings. The pCRA it discloses differs from the structure of the pCRA in claim 10 of the auxiliary request in that the electrophilic group is not reactive, see page 284, top left. The subject-matter of claim 10 is thus not anticipated by the disclosure of document D15.

Allowability of the appeal

24. In the board's judgement none of the further objections raised in the decision under appeal (under Articles 123(2), 53(c) and 84 EPC, see section IV) apply to the claims of the auxiliary request as the subject-matter objected to has been either amended or deleted.

25. The appeal is thus found to be allowable.

Remittal (Article 111(1) EPC)

26. Pursuant to Article 111(1) EPC, following the examination as to the allowability of the appeal, the board will decide on the appeal and, in this respect, it may either exercise any power within the competence of the department which was responsible for the decision or remit the case for further prosecution.

27. In a case such as the present one, where the examining division has dealt with inventive step only in the form of an obiter dictum and with the requirements of Article 83 EPC not at all, the board, exercising its discretion under Article 111(1), second sentence, EPC, decides to remit the case to the examining division for further prosecution, thereby giving the appellants the possibility of having their case heard by two instances.

28. The case is accordingly remitted to the examining division for further prosecution on the basis of the claims of the auxiliary request.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the examining division for further prosecution on the basis of the set of claims of the auxiliary request filed at the oral proceedings at 17:45 hrs.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility